NEU 1.54% $19.86 neuren pharmaceuticals limited

Phase 3 initiated

  1. 257 Posts.
    lightbulb Created with Sketch. 12
    From Acadia earnings...

    Initiated Phase 3 LAVENDER Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder



 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.